Heart Failure and Cardiac Transplantation
Yale has an active transplant program and provides continuity of care to more than 700 outpatients with heart failure.
Heart failure and transplant-related research at Yale consists of six ongoing studies, including investigations of:
Left ventricular assist devices/systems (LVAD/LVAS)
- DuraHeart LVAS – Evaluation of the safety and effectiveness of the DuraHeart™ left ventricular assist device in patients with advanced heart failure
- DuraHeart-2 Bridge to Transplant LVAD Trial
- Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass Trial – Evaluation of the safety and effectiveness of the CentriMag ventricular assist system in patients who have experienced heart failure during surgery and cannot be removed from cardiac bypass.
- Heartware Destination Therapy Trial – Trial of an LVAD as destination therapy in patients with advanced heart failure who have failed medical therapy and are not eligible for cardiac transplantation
- HeartMate III – Evaluation of the Heartmate III LVAD, featuring a magnetically levitated impeller
- INTERMACS - A national registry for patients receiving mechanical circulatory support device therapy to treat advanced heart failure (a joint effort of the NHLBI, CMS, and FDA)